Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review)

Molecular Membrane Biology

Volumn 27, Issue 7, 2010, Pages 312-327

  Huang, Ryan B ^a   Mocherla, Supriya ^a   Heslinga, Michael J ^a   Charoenphol, Phapanin ^a   Eniola Adefeso, Omolola ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

endothelial cells; margination; nanoparticle; Vascular targeting

Indexed keywords

CALCIUM CARBONATE; CARBON NANOTUBE; CD31 ANTIGEN; FULLERENE; GOLD; IRON OXIDE; MACROGOL; NANOCARRIER; NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; QUANTUM DOT; SILICON DIOXIDE;

BLOOD VESSEL WALL; CELL INTERACTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENDOSOME; ERYTHROCYTE; HEMODYNAMICS; HEMOLYSIS; HUMAN; MOLECULAR DYNAMICS; NANOFABRICATION; OPSONIZATION; PARTICLE SIZE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSCYTOSIS;

ANIMALS; BLOOD CELLS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; MICE; NANOMEDICINE; NANOPARTICLES;

EID: 78049338489     PISSN: 09687688     EISSN: 14645203     Source Type: Journal    
DOI: 10.3109/09687688.2010.522117     Document Type: Review

References (162)

1. Aarts PA, Van Den Broek SA, Prins GW, Kuiken GD, Sixma JJ, Heethaar RM. 1988. Blood platelets are concentrated near the wall, red blood cells, in the center in flowing blood. Arteriosclerosis 8:819-824.
2. Abbitt KB, Nash GB. 2003. Rheological properties of the blood influencing selectin-mediated adhesion of flowing leukocytes. Am J Physiol Heart Circ Physiol 285:H229-240.
3. Acharya G, Shin CS, McDermott M, Mishra H, Park H, Kwon IC, Park K. 2010. The hydrogel template method for fabrication of homogeneous nano/microparticles. J Control Release 141: 314-319.
4. Agashe HB, Dutta T, Garg M, Jain NK. 2006. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol 58: 1491-1498.
5. Akinc A, Thomas M, Klibanov AM, Langer R. 2005. Exploring polyethylenimine-mediated DNA transfection, the proton sponge hypothesis. J Gene Med 7:657-663.
6. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance, biodistribution of polymeric nanoparti-cles. Mol Pharm 5:505-15.
7. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. 2001. Interaction of poly(butylcyanoacrylate) nano-particles with the blood-brain barrier in vivo, in vitro. J Drug Target 9:209-221.
8. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. 2008. Porous silicon in drug delivery devices, materials. Adv Drug Deliv Rev 60:1266-1277.
9. Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM. 2005. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4:1423-1429.
10. Bareford LM, Swaan PW. 2007. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59:748-758.
11. Bermejo JF, Ortega P, Chonco L, Eritja R, Samaniego R, Mullner M, De Jesus E, De la Mata FJ, Flores JC, Gomez R, Munoz-Fernandez A. 2007. Water-soluble carbosilane dendri-mers: synthesis biocompatibility, complexation with oligonu-cleotides; evaluation for medical applications. Chemistry 13:483-495.
12. Bhaskar S, Hitt J, Chang SW, Lahann J. 2009. Multicompartmental microcylinders. Angew Chem Int Ed Engl 48:4589-4593.
13. Bihari P, Holzer M, Praetner M, Fent J, Lerchenberger M, Reichel CA, Rehberg M, Lakatos S, Krombach F. 2009. Single-walled carbon nanotubes activate platelets, accelerate thrombus formation in the microcirculation. Toxicology 269:148-154.
14. Bogdanov AA, Jr., Lin CP, Kang HW. 2007. Optical imaging of the adoptive transfer of human endothelial cells in mice using anti-human CD31 monoclonal antibody. Pharm Res 24: 1186-1192.
15. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 1995. A versatile vector for gene, oligo-nucleotide transfer into cells in culture, in vivo: polyethyleni-mine. Proc Natl Acad Sci USA 92:7297-7301.
16. Brown DM, Wilson MR, MacNee W, Stone V, Donaldson K. 2001. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area, oxida-tive stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol 175:191-199.
17. Buehler PW, Vallelian F, Mikolajczyk MG, Schoedon G, Schweizer T, Alayash AI, Schaer DJ. 2008. Structural stabilization in tetrameric or polymeric hemoglobin determines its interaction with endogenous antioxidant scavenger pathways. Antioxid Redox Signal 10:1449-1462.
18. Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615-1626.
19. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates, affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104:2050-2055.
20. Champion JA, Katare YK, Mitragotri S. 2007. Making polymeric micro-, nanoparticles of complex shapes. Proc Natl Acad Sci USA 104:11901-11904.
21. Champion JA, Mitragotri S. 2006. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 103:4930-4934.
22. Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee JW, Cheng J, Golomb G, Libby P, Langer R, Farokhzad OC. 2010. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci USA 107:2213-2218.
23. Charoenphol P, Huang RB, Eniola-Adefeso O. 2010. Potential role of size, hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials 31:1392-1402.
24. Chen B, Pogue BW, Hoopes PJ, Hasan T. 2006. Vascular, cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 16:279-305.
25. Cheng Y, A CS, Meyers JD, Panagopoulos I, Fei B, Burda C. 2008. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 130:10643-10647.
26. Cheng Y, Samia AC, Li J, Kenney ME, Resnick A, Burda C. 2009. Delivery, efficacy of a cancer drug as a function of the bond to the gold nanoparticle surface. Langmuir 26:2248-2255.
27. Chithrani BD, Ghazani AA, Chan WC. 2006. Determining the size, shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 6:662-668.
28. Cho Y, Shi R, Borgens RB, Ivanisevic A. 2008. Functionalized mesoporous silica nanoparticle-based drug delivery system to rescue acrolein-mediated cell death. Nanomedicine 3: 507-519.
29. Chouly C, Bordenave L, Bareille R, Guerin V, Baquey A, Pouliquen D, Baquey C, Jallet P. 1994. In vitro study of the hemocompatibility of superparamagnetic contrast agent for magnetic resonance imaging. Clin Mater 15:293-301.
30. Coleman L. 2008. Nutrition, rheumatic disease (nutrition, health). Totowa, NJ: Humana Press.
31. Cotter MJ, Muruve DA. 2005. The induction of inflammation by adenovirus vectors used for gene therapy. Front Biosci 10: 1098-1105.
32. Davi G, Patrono C. 2007. Platelet activation, atherothrombosis. N Engl J Med 357:2482-2494.
33. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. 2010. Size, shape effects in the biodistribution of intravascularly injected particles. J Control Release 141: 320-327.
34. Decuzzi P, Pasqualini R, Arap W, Ferrari M. 2009. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26:235-243.
35. Demos SM, Alkan-Onyuksel H, Kane BJ, Ramani K, Nagaraj A, Greene R, Klegerman M, McPherson DD. 1999. In vivo targeting of acoustically reflective liposomes for intravascular, transvascular ultrasonic enhancement. J Am Coll Cardiol 33:867-875.
36. Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. 2008. Metho-trexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy, intratumoral transport capability. Mol Pharm 5:105-116.
37. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. 2008. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 130: 11467-11476.
38. Diebold Y, Jarrin M, Saez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ. 2007. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP. Biomaterials 28:1553-1564.
39. Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, Hammer DA. 1999. Polymersomes: tough vesicles made from diblock copolymers. Science 284:1143-1146.
40. Domanski DM, Klajnert B, Bryszewska M. 2004. Influence of PAMAM dendrimers on human red blood cells. Bioelectro-chemistry 63:189-191.
41. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. 2007. Influence of poly (ethylene glycol) grafting density, polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 1768:1367-1377.
42. Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H, Simone E, Nakada MT, Fisher A, Albelda SM, Muzykantov VR. 2008. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29:215-227.
43. Eckstein EC, Tilles AW, Millero FJ, 3rd. 1988. Conditions for the occurrence of large near-wall excesses of small particles during blood flow. Microvasc Res 36:31-39.
44. Einav S, Bluestein D. 2004. Dynamics of blood flow, platelet transport in pathological vessels. Ann N Y Acad Sci 1015:351-366.
45. Eniola AO, Krasik EF, Smith LA, Song G, Hammer DA. 2005. I-domain of lymphocyte function-associated antigen-1 mediates rolling of polystyrene particles on ICAM-1 under flow. Biophys J 89:3577-3588.
46. Eniola AO, Rodgers SD, Hammer DA. 2002. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes. Biomaterials 23:2167-2177.
47. Everts M, Schraa A, De Leij L, Meijer D, Molema G. 2001. Vascular endothelium in inflamed tissue as a target for site selective delivery of drugs. In: Molema G (ed.) Drug targeting: organ-specific strategies. Germany: Wiley-VCH.
48. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. 2006. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight, particle size. Eur J Pharm Sci 27:27-36.
49. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D. 1999. Evaluation of effect of charge, lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 291:1017-1022.
50. Gaspard J, Hahn MS, Silas JA. 2009. Polymerization of hydrogels inside self-assembled block copolymer vesicles. Langmuir 25:12878-12884.
51. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. 2007. Shape effects of filaments versus spherical particles in flow, drug delivery. Nat Nanotechnol 2:249-255.
52. Gentile F, Curcio A, Indolfi C, Ferrari M, Decuzzi P. 2008. The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnology 6:9.
53. Gillies ER, Frechet JM. 2005. Dendrimers, dendritic polymers in drug delivery. Drug Discov Today 10:35-43.
54. Gimbrone MA, Jr., Topper JN, Nagel T, erson KR, Garcia-Cardena G. 2000. Endothelial dysfunction, hemody-namic forces, atherogenesis. Ann NY Acad Sci 902:230-239; discussion 9-40.
55. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. 2001. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxoru-bicin versus topotecan. J Clin Oncol 19:3312-3322.
56. Gosk S, Moos T, Gottstein C, Bendas G. 2008. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 1778:854-863.
57. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM. 2007. Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J Control Release 121:10-18.
58. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. 2008. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613-11618.
59. Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. 2009. Antiangiogenic properties of silver nanoparticles. Biomaterials 30:6341-6350.
60. Hajitou A, Pasqualini R, Arap W. 2006. Vascular targeting: recent advances, therapeutic perspectives. Trends Cardiovasc Med 16:80-88.
61. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. 2008. Surface charge of nanoparticles determines their endocytic, transcytotic pathway in polarized MDCK cells. Biomacro-molecules 9:435-443.
62. He Q, Zhang J, Shi J, Zhu Z, Zhang L, Bu W, Guo L, Chen Y. 2010. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins, cellular responses. Biomaterials 31:1085-1092.
63. He XW, Liu T, Xiao Y, Feng YL, Cheng DJ, Tingting G, Zhang L, Zhang Y, Chen YX. 2009. Vascular endothelial growth factor-C siRNA delivered via calcium carbonate nanoparticle effectively inhibits lymphangiogenesis, growth of colorectal cancer in vivo. Cancer Biother Radiopharm 24:249-259.
64. Heslinga MJ, Mastria EM, Eniola-Adefeso O. 2009. Fabrication of biodegradable spheroidal microparticles for drug delivery applications. J Control Release 138:235-242.
65. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. 2002. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants, capsid. Hum Gene Ther 13:129-141.
66. Hoffman GS, Weyand CM. 2002. Inflammatory disease of blood vessels New York, NY: Marcel Dekker.
67. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR, Jr., Banaszak Holl MM. 2007. The binding avidity of a nanoparti-cle-based multivalent targeted drug delivery platform. Chem Biol 14:107-115.
68. Hsu SH, Tang CM, Tseng HJ. 2006. Biocompatibility of poly (ether)urethane-gold nanocomposites. J Biomed Mater Res A 79:759-770.
69. Jallouli Y, Paillard A, Chang J, Sevin E, Betbeder D. 2007. Influence of surface charge, inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm 344:103-109.
70. Jennings LK. 2009. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102:248-257.
71. Jiang G, Park K, Kim J, Kim KS, Hahn SK. 2009. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm 6:727-737.
72. Jugdaohsingh R. 2007. Silicon, bone health. J Nutr Health Aging 11:99-110.
73. Kagan VE, Bayir H, Shvedova AA. 2005. Nanomedicine, nanotox-icology: two sides of the same coin. Nanomedicine 1:313-316.
74. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA. 2010. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 31:3079-3086.
75. Kannan R, Navath R, Kurtoglu Y, Dai H, Wang B, Kannan S, Romero R. 2009. PAMAM dendrimers for brain delivery of therapeutics for the treatment of cerebral palsy: chemistry, in vivo efficacy, imaging. In: 61st AIChE Annual Meeting, 2009, Nashville, TN.
76. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR. 2007. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116:276-284.
77. Kaul G, Amiji M. 2005. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: in vitro, in vivo studies. Pharm Res 22:951-961.
78. Ke W, Shao K, Huang R,Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C. 2009. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoa-mine dendrimer. Biomaterials 30:6976-6985.
79. Kilpelainen M, Riikonen J, Vlasova MA, Huotari A, Lehto VP, Salonen J, Herzig KH, Jarvinen K. 2009. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon micropar-ticles. J Control Release 137:166-170.
80. Kim D, El-Shall H, Dennis D, Morey T. 2005. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces 40:83-91.
81. Kirkham M, Parton RG. 2005. Clathrin-independent endocytosis: new insights into caveolae, non-caveolar lipid raft carriers. Biochim Biophys Acta 1745:273-286.
82. Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M. 2009. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog 5:e1000417.
83. Koziara JM, Oh JJ, Akers WS, Ferraris SP, Mumper RJ. 2005. Blood compatibility of cetyl alcohol/polysorbate-based nanopar-ticles. Pharm Res 22:1821-1828.
84. Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R, Windisch M, Hammer A, Malle E, Zimmer A, Sattler W. 2007. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake, transcytosis in an in vitro model of the blood-brain barrier. J Control Release 117:301-311.
85. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325.
86. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS, Hoffman AS. 2002. pH-sensitive polymers that enhance intra-cellular drug delivery in vivo. J Control Release 78:295-303.
87. Lackey CA, Press OW, Hoffman AS, Stayton PS. 2002. A biomimetic pH-responsive polymer directs endosomal release, intracellular delivery of an endocytosed antibody complex. Bioconjug Chem 13:996-1001.
88. Langeggen H, Namork E, Johnson E, Hetland G. 2003. HUVEC take up opsonized zymosan particles, secrete cytokines IL-6, IL-8 in vitro. FEMS Immunol Med Microbiol 36:55-61.
89. Lee SY, Ferrari M, Decuzzi P. 2009. Design of bio-mimetic particles with enhanced vascular interaction. J Biomech 42:1885-1890.
90. Lee SY, Ferrari M, Decuzzi P. 2009. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotech-nology 20:495101.
91. Lewinski N, Colvin V, Drezek R. 2008. Cytotoxicity of nanopar-ticles. Small 4:26-49.
92. Li SD, Chen YC, Hackett MJ, Huang L. 2008. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16:163-169.
93. Li SD, Huang L. 2009. Nanoparticles evading the reticuloendo-thelial system: role of the supported bilayer. Biochim Biophys Acta 1788:2259-2266.
94. Lim J, Guo Y, Rostollan CL, Stanfield J, Hsieh JT, Sun X, Simanek EE. 2008. The role of the size, number of polyethylene glycol chains in the biodistribution, tumor localization of tri-azine dendrimers. Mol Pharm 5:540-547.
95. Liu J, Jiang X, Ashley C, Brinker CJ. 2009. Electrostatically mediated liposome fusion, lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, delivery. J Am Chem Soc 131:7567-7569.
96. Ljubimova JY, Fujita M, Khazenzon NM, Lee BS, Wachsmann-Hogiu S, Farkas DL, Black KL, Holler E. 2008. Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact 171:195-203.
97. Lu W, Sun Q, Wan J, She Z, Jiang XG. 2006. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 66:11878-11887.
98. Lu W, Tan YZ, Hu KL, Jiang XG. 2005. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability, little toxicity against blood-brain barrier. Int J Pharm 295: 247-260.
99. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. 2008. Nanoparticle size, surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 105:14265-14270.
100. Manchester M, Singh P. 2006. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev 58:1505-1522.
101. Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Frohlich E. 2009. The role of nanoparticle size in hemocompat-ibility. Toxicology 258:139-147.
102. Migliorini C, Qian Y, Chen H, Brown EB, Jain RK, Munn LL. 2002. Red blood cells augment leukocyte rolling in a virtual blood vessel. Biophys J 83:1834-1841.
103. Miyamoto M, Sasakawa S, Ozawa T, Kawaguchi H, Ohtsuka Y. 1989. Platelet aggregation induced by latex particles. I. Effects of size, surface potential, hydrophobicity of particles. Biomaterials 10:251-257.
104. Movat HZ, Weiser WJ, Glynn MF, Mustard JF. 1965. Platelet phagocytosis, aggregation. J Cell Biol 27:531-543.
105. Munn LL, Melder RJ, Jain RK. 1996. Role of erythrocytes in leukocyte-endothelial interactions: mathematical model, experimental validation. Biophys J 71:466-478.
106. Muro S, Gajewski C, Koval M, Muzykantov VR. 2005. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery, prolonged effects of drugs. Blood 105:650-658.
107. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. 2008. Control of endothelial targeting, intracellular delivery of therapeutic enzymes by modulating the size, shape of ICAM-1-targeted carriers. Mol Ther 16:1450-1458.
108. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA. 2008. Nanoparti-cle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105:9343-9348.
109. Muzykantov VR. 2001. Targeting of superoxide dismutase, catalase to vascular endothelium. J Control Release 71:1-21.
110. Nemmar A, Melghit K, Ali BH. 2008. The acute proinflammatory, prothrombotic effects of pulmonary exposure to rutile TiO2 nanorods inrats. Exp Biol Med (Maywood) 233:610-619.
111. Nishikawa T, Iwakiri N, Kaneko Y, Taguchi A, Fukushima K, Mori H, Morone N, Kadokawa J. 2009. Nitric oxide release in human aortic endothelial cells mediated by delivery of amphi-philic polysiloxane nanoparticles to caveolae. Biomacromole-cules 10:2074-2085.
112. Ondaral S, Wagberg L, Enarsson LE. 2006. The adsorption of hyperbranched polymers on silicon oxide surfaces. J Colloid Interface Sci 301:32-39.
113. Pack DW, Putnam D, Langer R. 2000. Design of imidazole-containing endosomolytic biopolymers for gene delivery. Bio-technol Bioeng 67:217-223.
114. Pappu V, Bagchi P. 2007. Hydrodynamic interaction between erythrocytes, leukocytes affects rheology of blood in microves-sels. Biorheology 44:191-215.
115. Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. 2009. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 8:331-336.
116. Partlow KC, Lanza GM, Wickline SA. 2008. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 29:3367-3375.
117. Patil Y, Sadhukha T, Ma L, Panyam J. 2009. Nanoparticle-mediated simultaneous, targeted delivery of paclitaxel, tariqui-dar overcomes tumor drug resistance. J Control Release 136:21-29.
118. Pearson MJ, Lipowsky HH. 2000. Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery. Am J Physiol Heart Circ Physiol 279:H1460-471.
119. Pedro L, Soares SS, Ferreira GNM. 2008. Purification of biona-noparticles. Chem Eng Technol 31:815-825.
120. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. 2009. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci USA 106:9815-9819.
121. Peters K, Unger RE, Kirkpatrick CJ, Gatti AM, Monari E. 2004. Effects of nano-scaled particles on endothelial cell function in vitro: studies on viability, proliferation, inflammation. J Mater Sci Mater Med 15:321-325.
122. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. 2003. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 90:323-334.
123. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, Radomski MW. 2005. Nanoparticle-induced platelet aggregation, vascular thrombosis. Br J Pharmacol 146: 882-893.
124. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo YE, Woolliscroft MJ, Sugai JV, Johnson TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD. 2006. Vascular targeted nanoparticles for imaging, treatment of brain tumors. Clin Cancer Res 12: 6677-6686.
125. Rejman J, Bragonzi A, Conese M. 2005. Role of clathrin-, caveo-lae-mediated endocytosis in gene transfer mediated by lipo-, polyplexes. Mol Ther 12:468-474.
126. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. 2004. Size-dependent internalization of particles via the pathways of clathrin-, caveolae-mediated endocytosis. Biochem J 377:159-169.
127. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. 2005. Direct fabrication, harvesting of mono-disperse, shape-specific nanobiomaterials. J Am Chem Soc 127:10096-10100.
128. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. 2001. Atherosclerosis, cancer: common molecular pathways of disease development, progression. Ann NY Acad Sci 947:271-292; discussion 292-3.
129. Sakhalkar HS, Dalal MK, Salem AK, Ansari R, Fu J, Kiani MF, Kurjiaka DT, Hanes J, Shakesheff KM, Goetz DJ. 2003. Leukocyte-inspired biodegradable particles that selectively, avidly adhere to inflamed endothelium in vitro, in vivo. Proc Natl Acad Sci USA 100:15895-15900.
130. Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. 2008. Mesoporous silicon in drug delivery applications. J Pharm Sci 97:632-653.
131. Schwendener RA. 2007. Liposomes in biology, medicine. Adv Exp Med Biol 620:117-128.
132. Serda RE, Gu J, Bhavane RC, Liu X, Chiappini C, Decuzzi P, Ferrari M. 2009. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials 30:2440-2448.
133. Shcharbin D, Pedziwiatr E, Blasiak J, Bryszewska M. 2009. How to study dendriplexes II: transfection, cytotoxicity. J Control Release 141:110-127.
134. Shi X, Wang S, Meshinchi S, Van Antwerp ME, Bi X, Lee I, Baker JR, Jr. 2007. Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting, imaging. Small 3: 1245-1252.
135. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. 2009. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 3:1357-1364.
136. Shriver LP, Koudelka KJ, Manchester M. 2009. Viral nanoparticles associate with regions of inflammation, blood brain barrier disruption during CNS infection. J Neuroimmunol 211:66-72.
137. Simone E, Ding BS, Muzykantov V. 2009. Targeted delivery of therapeutics to endothelium. Cell Tissue Res 335:283-300.
138. Simone EA, Dziubla TD, Discher DE, Muzykantov VR. 2009. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromole-cules 10:1324-1330.
139. Smith BR, Heverhagen J, Knopp M, Schmalbrock P, Shapiro J, Shiomi M, Moldovan NI, Ferrari M, Lee SC. 2007. Localization to atherosclerotic plaque, biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed Microdevices 9:719-727.
140. Sonavane G, Tomoda K, Makino K. 2008. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 66:274-280.
141. Sonawane ND, Szoka FC, Jr., Verkman AS. 2003. Chloride accumulation, swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 278:4826-4831.
142. Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, Razavi R, Lanza G, Wickline SA. 2009. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine 5:359-367.
143. Srinivasan R, Marchant RE, Gupta AS. 2009. In vitro, in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res A 93:1004-1015.
144. Stan RV. 2006. Endocytosis pathways in endothelium: how many? Am J Physiol Lung Cell Mol Physiol 290:L806-808.
145. Stevens KN, Crespo-Biel O, Van Den Bosch EE, Dias AA, Knetsch ML, Aldenhoff YB, Van Der Veen FH, Maessen JG, Stobberingh EE, Koole LH. 2009. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles, the coagulation of contacting blood. Biomaterials 30:3682-3690.
146. Strother R, Matei D. 2009. Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag 5:639-650.
147. Sutton D, Nasongkla N, Blanco E, Gao J. 2007. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24:1029-1046.
148. Takeda M, Tada H, Higuchi H, Kobayashi Y, Kobayashi M, Sakurai Y, Ishida T, Ohuchi N. 2008. In vivo single molecular imaging, sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems, tailor-made medicine. Breast Cancer 15:145-52.
149. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MM, Decuzzi P, Tour JM, Robertson F, Ferrari M. 2008. Mesoporous silicon particles as a multistage delivery system for imaging, therapeutic applications. Nat Nanotechnol 3:151-157.
150. Traub LM. 2009. Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat Rev Mol Cell Biol 10:583-596.
151. Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J. 2004. Cardiac safety profile of prolonged (‡6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 94: 147-151.
152. Vargas A, Eid M, Fanchaouy M, Gurny R, Delie F. 2008. In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation properties, administration parameters, biological issues involved in PDT outcome. Eur J Pharm Biopharm 69:43-53.
153. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. 2005. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery. Pharm Res 22: 1906-1917.
154. Wagner DD, Frenette PS. 2008. The vessel wall, its interactions. Blood 111:5271-5281.
155. Wang P, Xue Y, Shang X, Liu Y. 2009. Diphtheria toxin mutant CRM197-mediated transcytosis across blood-brain barrier in vitro. Cell Mol Neurobiol 30:717-725.
156. Wilhelm C, Bal L, Smirnov P, Galy-Fauroux I, Clement O, Gazeau F, Emmerich J. 2007. Magnetic control of vascular network formation with magnetically labeled endothelial progenitor cells. Biomaterials 28: 3797-3806.
157. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. 2006. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26:2103-2109.
158. Wiwanitkit V, Sereemaspun A, Rojanathanes R. 2009. Gold nano-particles, a microscopic view of platelets: a preliminary observation. Cardiovasc J Afr 20:141-142.
159. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: molecular size dependence, cutoff size. Cancer Res 55:3752-3756.
160. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J. 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis, are delivered to neurones. J Control Release 137:78-86.
161. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. 2008. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem 19:145-152.
162. Zhu J, Xue J, Guo Z, Zhang L, Marchant RE. 2007. Biomimetic glycoliposomes as nanocarriers for targeting P-selectin on activated platelets. Bioconjug Chem 18: 1366-1369.